Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Recruiting 6Suspended 3Not yet recruiting 2Active not recruiting 2Terminated 1

Sponsor Class

OTHER 8INDUSTRY 4NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Myeloid 1Classical hematology 1

Conditions

Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Myelodysplastic Syndromes 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Acute 1Anemia, Refractory, with Excess of Blasts 1

Interventions

Specimen Handling 188Magnetic Resonance Spectroscopy 143Biopsy 116Nivolumab 39X-Rays 29Immunoglobulin G 29Disulfides 29Radiation 28Carboplatin 27atezolizumab 25Taxes 25Paclitaxel 25pembrolizumab 23Radiotherapy 23Ipilimumab 23CTLA-4 Antigen 23olaparib 22Cyclophosphamide 22Cisplatin 21Platinum 20Gemcitabine 20Doxorubicin 20Bevacizumab 201,2-diaminocyclohexaneplatinum II citrate 20Phantoms, Imaging 19Vincristine 17trametinib 16cabozantinib 15Rituximab 15ibrutinib 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Active not recruiting × NIH × decitabine and cedazuridine drug combination × Clear all
NCT05600894 2026-05-13

Venetoclax in Combination With ASTX727 for the Treatment of Chronic Myelomonocytic Leukemia and Other Myelodysplastic Syndrome/Myeloproliferative Neoplasm

National Cancer Institute (NCI)

Phase 2 Active not recruiting
132 enrolled
Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Refractory, with Excess of Blasts, Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myelomonocytic, Chronic, Myelodysplastic-Myeloproliferative Diseases

NCT04817241 2025-11-10

Testing Oral Decitabine and Cedazuridine (ASTX727) in Combination With Venetoclax for Higher-Risk Acute Myeloid Leukemia Patients

National Cancer Institute (NCI)

Phase 1/2 Active not recruiting
5 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡